Exane Derivatives Exact Sciences Corp Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Exact Sciences Corp stock. As of the latest transaction made, Exane Derivatives holds 35 shares of EXAS stock, worth $2,172. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35
Previous 2,900
98.79%
Holding current value
$2,172
Previous $202,000
99.5%
% of portfolio
0.0%
Previous 0.06%
Shares
4 transactions
Others Institutions Holding EXAS
# of Institutions
672Shares Held
163MCall Options Held
2.58MPut Options Held
2.19M-
Vanguard Group Inc Valley Forge, PA17.8MShares$1.1 Billion0.02% of portfolio
-
Capital World Investors Los Angeles, CA15.8MShares$983 Million0.17% of portfolio
-
Wellington Management Group LLP Boston, MA14.3MShares$890 Million0.18% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$749 Million0.01% of portfolio
-
State Street Corp Boston, MA6.68MShares$415 Million0.02% of portfolio
About EXACT SCIENCES CORP
- Ticker EXAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 176,960,000
- Market Cap $11B
- Description
- Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...